{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:35:02Z","timestamp":1791909302342,"version":"4.3.4"},"reference-count":217,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"USERN Foundation Houston TX USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03234-3","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:47:39Z","timestamp":1753699659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Interplay between innate-like T-cells and microRNAs in cancer immunity"],"prefix":"10.1007","volume":"16","author":[{"given":"Mohammad Javad","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashmin","family":"Afshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirmohammad","family":"Amoozadehsamakoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4159-7299","authenticated-orcid":false,"given":"Kiarash","family":"Saleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"3234_CR1","doi-asserted-by":"crossref","unstructured":"Loh L, Carcy S, Krovi HS, Domenico J, Spengler A, Lin Y, et al. Unraveling the phenotypic states of human innate-like T cells: comparative insights with conventional T cells and mouse models. bioRxiv. 2023.","DOI":"10.1101\/2023.12.07.570707"},{"issue":"1","key":"3234_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cei\/uxad058","volume":"213","author":"C-P Hackstein","year":"2023","unstructured":"Hackstein C-P, Klenerman P. MAITs and their mates: \u201cInnate-like\u201d behaviors in conventional and unconventional T cells. Clin Exp Immunol. 2023;213(1):1\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"3234_CR3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192336","volume":"217","author":"R Ruscher","year":"2020","unstructured":"Ruscher R, Lee ST, Salgado OC, Breed ER, Osum SH, Hogquist KA. Intestinal CD8\u03b1\u03b1 IELs derived from two distinct thymic precursors have staggered ontogeny. J Exp Med. 2020;217(8): e20192336.","journal-title":"J Exp Med"},{"issue":"7908","key":"3234_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-022-04632-1","volume":"605","author":"C Chou","year":"2022","unstructured":"Chou C, Zhang X, Krishna C, Nixon BG, Dadi S, Capistrano KJ, et al. Programme of self-reactive innate-like T cell-mediated cancer immunity. Nature. 2022;605(7908):139\u201345.","journal-title":"Nature"},{"issue":"12","key":"3234_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","volume":"24","author":"R Shang","year":"2023","unstructured":"Shang R, Lee S, Senavirathne G, Lai EC. microRNAs in action: biogenesis, function and regulation. Nat Rev Genet. 2023;24(12):816\u201333.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"3234_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00262-021-02991-8","volume":"71","author":"J Li","year":"2022","unstructured":"Li J, Sun L, Chen Y, Zhu J, Shen J, Wang J, et al. Gastric cancer-derived exosomal miR-135b-5p impairs the function of V\u03b39V\u03b42 T cells by targeting specificity protein 1. Cancer Immunol Immunother. 2022;71(2):311\u201325.","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"3234_CR7","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.3748\/wjg.v19.i20.2985","volume":"19","author":"J Raisch","year":"2013","unstructured":"Raisch J, Darfeuille-Michaud A, Nguyen HT. Role of micrornas in the immune system, inflammation and cancer. World J Gastroenterol. 2013;19(20):2985\u201396.","journal-title":"World J Gastroenterol"},{"key":"3234_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.619220","volume":"8","author":"J Wang","year":"2021","unstructured":"Wang J, Li K, Zhang X, Li G, Liu T, Wu X, et al. Microrna-155 controls iNKT cell development and lineage differentiation by coordinating multiple regulating pathways. Front Cell Dev Biol. 2021;8: 619220.","journal-title":"Front Cell Dev Biol"},{"key":"3234_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.670531","volume":"9","author":"T Liu","year":"2021","unstructured":"Liu T, Wang J, Subedi K, Yi Q, Zhou L, Mi QS. Microrna-155 regulates MAIT1 and MAIT17 cell differentiation. Front Cell Dev Biol. 2021;9: 670531.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"3234_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/ni.3565","volume":"17","author":"HF Koay","year":"2016","unstructured":"Koay HF, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat Immunol. 2016;17(11):1300\u201311.","journal-title":"Nat Immunol"},{"issue":"85","key":"3234_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo4365","volume":"8","author":"L Perriman","year":"2023","unstructured":"Perriman L, Tavakolinia N, Jalali S, Li S, Hickey PF, Amann-Zalcenstein D, et al. A three-stage developmental pathway for human V\u03b39V\u03b42 T cells within the postnatal thymus. Sci Immunol. 2023;8(85): eabo4365.","journal-title":"Sci Immunol"},{"issue":"4","key":"3234_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ncrna.2023.07.002","volume":"8","author":"I Gareev","year":"2023","unstructured":"Gareev I, de Jesus Encarnacion Ramirez M, Goncharov E, Ivliev D, Shumadalova A, Ilyasova T, Wang C. MiRNAs and lncRNAs in the regulation of innate immune signaling. Non-coding RNA Res. 2023;8(4):534\u201341.","journal-title":"Non-coding RNA Res"},{"issue":"1","key":"3234_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-021-00240-1","volume":"18","author":"C Kim","year":"2021","unstructured":"Kim C, Ye Z, Weyand CM, Goronzy JJ. MiR-181a-regulated pathways in T-cell differentiation and aging. Immunity Ageing. 2021;18(1): 28.","journal-title":"Immunity Ageing"},{"issue":"1","key":"3234_CR14","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202052234","volume":"23","author":"G Gordino","year":"2022","unstructured":"Gordino G, Costa-Pereira S, Corredeira P, Alves P, Costa L, Gomes AQ, et al. MicroRNA-181a restricts human \u03b3\u03b4 T cell differentiation by targeting Map3k2 and Notch2. EMBO Rep. 2022;23(1): e52234.","journal-title":"EMBO Rep"},{"issue":"7","key":"3234_CR15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ccell.2022.05.017","volume":"40","author":"M Molgora","year":"2022","unstructured":"Molgora M, Colonna M. Innate-like T cells: a promising asset in anti-cancer immunity. Cancer Cell. 2022;40(7):714\u20136.","journal-title":"Cancer Cell"},{"issue":"6","key":"3234_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41568-023-00562-w","volume":"23","author":"B Ruf","year":"2023","unstructured":"Ruf B, Greten TF, Korangy F. Innate lymphoid cells and innate-like T cells in cancer\u2014at the crossroads of innate and adaptive immunity. Nat Rev Cancer. 2023;23(6):351\u201371.","journal-title":"Nat Rev Cancer"},{"key":"3234_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/720803","volume":"2012","author":"KA Pilones","year":"2012","unstructured":"Pilones KA, Aryankalayil J, Demaria S. Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol. 2012;2012: 720803.","journal-title":"Clin Dev Immunol"},{"issue":"7","key":"3234_CR18","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.21873\/anticanres.12719","volume":"38","author":"K Yamashita","year":"2018","unstructured":"Yamashita K, Arimoto A, Nishi M, Tanaka T, Fujita M, Fukuoka E, et al. Application of iNKT cell-targeted active immunotherapy in cancer treatment. Anticancer Res. 2018;38(7):4233\u20139.","journal-title":"Anticancer Res"},{"issue":"2","key":"3234_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nri3369","volume":"13","author":"PJ Brennan","year":"2013","unstructured":"Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013;13(2):101\u201317.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"3234_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1348-0421.2011.00338.x","volume":"55","author":"Y Kinjo","year":"2011","unstructured":"Kinjo Y, Ueno K. iNKT cells in microbial immunity: recognition of microbial glycolipids. Microbiol Immunol. 2011;55(7):472\u201382.","journal-title":"Microbiol Immunol"},{"key":"3234_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fimmu.2018.00519","volume":"9","author":"L Van Kaer","year":"2018","unstructured":"Van Kaer L, Wu L. Therapeutic potential of invariant natural killer T cells in autoimmunity. Front Immunol. 2018;9:519.","journal-title":"Front Immunol"},{"key":"3234_CR22","first-page":"269","volume":"314","author":"EH Meyer","year":"2007","unstructured":"Meyer EH, DeKruyff RH, Umetsu DT. iNKT cells in allergic disease. Curr Top Microbiol Immunol. 2007;314:269\u201391.","journal-title":"Curr Top Microbiol Immunol"},{"key":"3234_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.754106","volume":"12","author":"T Goto","year":"2021","unstructured":"Goto T, Ito Y, Satoh M, Nakamoto S, Nishizawa N, Hosono K, et al. Activation of iNKT cells facilitates liver repair after hepatic ischemia reperfusion injury through acceleration of macrophage polarization. Front Immunol. 2021;12: 754106.","journal-title":"Front Immunol"},{"key":"3234_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101342","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang G, Chai D, Dang Y, Zheng J, Li H. iNKT: a new avenue for CAR-based cancer immunotherapy. Transl Oncol. 2022;17: 101342.","journal-title":"Transl Oncol"},{"key":"3234_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2020.12.010","volume":"130","author":"GF Painter","year":"2021","unstructured":"Painter GF, Burn OK, Hermans IF. Using agonists for iNKT cells in cancer therapy. Mol Immunol. 2021;130:1\u20136.","journal-title":"Mol Immunol"},{"key":"3234_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.897750","volume":"9","author":"G Delfanti","year":"2022","unstructured":"Delfanti G, Dellabona P, Casorati G, Fedeli M. Adoptive immunotherapy with engineered iNKT cells to target cancer cells and the suppressive microenvironment. Front Med. 2022;9: 897750.","journal-title":"Front Med"},{"key":"3234_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915837","volume":"13","author":"J Saura-Esteller","year":"2022","unstructured":"Saura-Esteller J, De Jong M, King LA, Ensing E, Winograd B, De Gruijl TD, et al. Gamma delta T-cell based cancer immunotherapy: past-present-future. Front Immunol. 2022;13: 915837.","journal-title":"Front Immunol"},{"issue":"5","key":"3234_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051206","volume":"9","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zhang C. The role of human \u03b3\u03b4 T cells in anti-tumor immunity and their potential for cancer immunotherapy. Cells. 2020;9(5): 1206.","journal-title":"Cells"},{"key":"3234_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100961","author":"R Lameris","year":"2023","unstructured":"Lameris R, Ruben JM, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp FS, et al. A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies. Cell Rep Med. 2023. https:\/\/doi.org\/10.1016\/j.xcrm.2023.100961.","journal-title":"Cell Rep Med"},{"issue":"1","key":"3234_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/discim\/kyad011","volume":"2","author":"S Alonso","year":"2023","unstructured":"Alonso S, Edelblum KL. Metabolic regulation of \u03b3\u03b4 intraepithelial lymphocytes. Discov Immunol. 2023;2(1): kyad011.","journal-title":"Discov Immunol"},{"key":"3234_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928441","volume":"13","author":"L Gay","year":"2022","unstructured":"Gay L, Mezouar S, Cano C, Frohna P, M\u00e8ge J-L, Olive D. Role of V\u03b39v\u03b42 T lymphocytes in infectious diseases. Front Immunol. 2022;13: 928441.","journal-title":"Front Immunol"},{"issue":"9","key":"3234_CR32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","volume":"20","author":"DI Godfrey","year":"2019","unstructured":"Godfrey DI, Koay H-F, McCluskey J, Gherardin NA. The biology and functional importance of MAIT cells. Nat Immunol. 2019;20(9):1110\u201328.","journal-title":"Nat Immunol"},{"issue":"2","key":"3234_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/cancers12020413","volume":"12","author":"Z Lukasik","year":"2020","unstructured":"Lukasik Z, Elewaut D, Venken K. MAIT cells come to the rescue in cancer immunotherapy? Cancers. 2020;12(2):413.","journal-title":"Cancers"},{"key":"3234_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01014","author":"TSC Hinks","year":"2020","unstructured":"Hinks TSC, Zhang X-W. MAIT cell activation and functions. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.01014.","journal-title":"Front Immunol"},{"key":"3234_CR35","doi-asserted-by":"publisher","first-page":"1369236","DOI":"10.3389\/fimmu.2024.1369236","volume":"15","author":"M Yigit","year":"2024","unstructured":"Yigit M, Basoglu OF, Unutmaz D. Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential. Front Immunol. 2024;15:1369236.","journal-title":"Front Immunol"},{"issue":"1","key":"3234_CR36","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1038\/s41467-021-25009-4","volume":"12","author":"EV Petley","year":"2021","unstructured":"Petley EV, Koay H-F, Henderson MA, Sek K, Todd KL, Keam SP, et al. MAIT cells regulate NK cell-mediated tumor immunity. Nat Commun. 2021;12(1):4746.","journal-title":"Nat Commun"},{"key":"3234_CR37","doi-asserted-by":"publisher","first-page":"1059042","DOI":"10.3389\/fimmu.2022.1059042","volume":"13","author":"Y Gui","year":"2022","unstructured":"Gui Y, Cheng H, Zhou J, Xu H, Han J, Zhang D. Development and function of natural TCR(+) CD8\u03b1\u03b1(+) intraepithelial lymphocytes. Front Immunol. 2022;13:1059042.","journal-title":"Front Immunol"},{"issue":"4","key":"3234_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1471-4906(02)02191-9","volume":"23","author":"GF Gao","year":"2002","unstructured":"Gao GF. CD8\u03b1\u03b1 and CD8\u03b1\u03b2: truly different? Trends Immunol. 2002;23(4):177.","journal-title":"Trends Immunol"},{"issue":"4","key":"3234_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ni.1997","volume":"12","author":"JE Konkel","year":"2011","unstructured":"Konkel JE, Maruyama T, Carpenter AC, Xiong Y, Zamarron BF, Hall BE, et al. Control of the development of CD8\u03b1\u03b1+ intestinal intraepithelial lymphocytes by TGF-\u03b2. Nat Immunol. 2011;12(4):312\u20139.","journal-title":"Nat Immunol"},{"issue":"7","key":"3234_CR40","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/ijc.22854","volume":"121","author":"NK Vudattu","year":"2007","unstructured":"Vudattu NK, Magalhaes I, Schmidt M, Seyfert-Margolis V, Maeurer MJ. Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer. 2007;121(7):1512\u20139.","journal-title":"Int J Cancer"},{"issue":"7","key":"3234_CR41","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00262-020-02540-9","volume":"69","author":"L Szeponik","year":"2020","unstructured":"Szeponik L, Akeus P, Rodin W, Raghavan S, Quiding-J\u00e4rbrink M. Regulatory T cells specifically suppress conventional CD8\u03b1\u03b2 T cells in intestinal tumors of APC(Min\/+) mice. Cancer Immunol Immunother. 2020;69(7):1279\u201392.","journal-title":"Cancer Immunol Immunother"},{"key":"3234_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00223","volume":"4","author":"LJ Walker","year":"2013","unstructured":"Walker LJ, Marrinan E, Muenchhoff M, Ferguson J, Kloverpris H, Cheroutre H, et al. CD8\u03b1\u03b1 expression marks terminally differentiated human CD8+ T cells expanded in chronic viral infection. Front Immunol. 2013;4: 223.","journal-title":"Front Immunol"},{"issue":"9","key":"3234_CR43","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CJI.0b013e31818883a1","volume":"31","author":"I Magalhaes","year":"2008","unstructured":"Magalhaes I, Vudattu NK, J\u00e4ger E, Maeurer MJ. Tumor antigen-specific T-cells are present in the CD8alphaalpha+ T-cell effector-memory pool. J Immunother. 2008;31(9):840\u20138.","journal-title":"J Immunother"},{"key":"3234_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619954","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Li G, Zhang J, Wu X, Chen X. The dual roles of human \u03b3\u03b4 T cells: anti-tumor or tumor-promoting. Front Immunol. 2020;11: 619954.","journal-title":"Front Immunol"},{"issue":"26","key":"3234_CR45","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/blood-2016-11-751065","volume":"129","author":"F Gorini","year":"2017","unstructured":"Gorini F, Azzimonti L, Delfanti G, Scarf\u00f2 L, Scielzo C, Bertilaccio MT, et al. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood. 2017;129(26):3440\u201351.","journal-title":"Blood"},{"issue":"7","key":"3234_CR46","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1111\/cas.14428","volume":"111","author":"T Aoki","year":"2020","unstructured":"Aoki T, Takami M, Takatani T, Motoyoshi K, Ishii A, Hara A, et al. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner. Cancer Sci. 2020;111(7):2223\u201333.","journal-title":"Cancer Sci"},{"issue":"3","key":"3234_CR47","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00262-022-03268-4","volume":"72","author":"V Stavrou","year":"2023","unstructured":"Stavrou V, Fultang L, Booth S, De Simone D, Bartnik A, Scarpa U, et al. Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment. Cancer Immunol Immunother. 2023;72(3):543\u201360.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"3234_CR48","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1182\/blood-2007-05-092866","volume":"111","author":"GJ Renukaradhya","year":"2008","unstructured":"Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host\u2019s innate antitumor immune response to a B-cell lymphoma. Blood. 2008;111(12):5637\u201345.","journal-title":"Blood"},{"issue":"7","key":"3234_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12272-019-01139-8","volume":"42","author":"EA Bae","year":"2019","unstructured":"Bae EA, Seo H, Kim IK, Jeon I, Kang CY. Roles of NKT cells in cancer immunotherapy. Arch Pharm Res. 2019;42(7):543\u20138.","journal-title":"Arch Pharm Res"},{"issue":"7","key":"3234_CR50","first-page":"2067","volume":"97","author":"M Nieda","year":"2001","unstructured":"Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, et al. TRAIL expression by activated human CD4+ V\u03b124NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood J Am Soc Hematol. 2001;97(7):2067\u201374.","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"3234_CR51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clim.2011.10.006","volume":"142","author":"FL Schneiders","year":"2012","unstructured":"Schneiders FL, de Bruin RC, Santegoets SJ, Bonneville M, Scotet E, Scheper RJ, et al. Activated iNKT cells promote V\u03b39V\u03b42-T cell anti-tumor effector functions through the production of TNF-\u03b1. Clin Immunol. 2012;142(2):194\u2013200.","journal-title":"Clin Immunol"},{"issue":"9","key":"3234_CR52","first-page":"1724","volume":"70","author":"X Yang","year":"2024","unstructured":"Yang X, Gu C, Zhang R, Yang X, Zhang Z. Analysis of Th1\/Th2 balance and related cytokine changes in the peripheral blood of patients with multiple myeloma. Clin Lab. 2024;70(9):1724.","journal-title":"Clin Lab"},{"key":"3234_CR53","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10753-014-9980-4","volume":"38","author":"P Feng","year":"2015","unstructured":"Feng P, Yan R, Dai X, Xie X, Wen H, Yang S. The alteration and clinical significance of Th1\/Th2\/Th17\/Treg cells in patients with multiple myeloma. Inflammation. 2015;38:705\u20139.","journal-title":"Inflammation"},{"issue":"2","key":"3234_CR54","first-page":"1580","volume":"15","author":"A Bojarska-Junak","year":"2018","unstructured":"Bojarska-Junak A, Waldowska M, Wo\u015b J, Chocholska S, Hus I, Tomczak W, et al. Intracellular IL-4 and IFN-\u03b3 expression in iNKT cells from patients with chronic lymphocytic leukemia. Oncol Lett. 2018;15(2):1580\u201390.","journal-title":"Oncol Lett"},{"issue":"5","key":"3234_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065075","volume":"8","author":"H Nur","year":"2013","unstructured":"Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, et al. Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. PLoS ONE. 2013;8(5): e65075.","journal-title":"PLoS ONE"},{"key":"3234_CR56","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3389\/fimmu.2017.01355","volume":"8","author":"PY Lam","year":"2017","unstructured":"Lam PY, Nissen MD, Mattarollo SR. Invariant natural killer T cells in immune regulation of blood cancers: harnessing their potential in immunotherapies. Front Immunol. 2017;8:1355.","journal-title":"Front Immunol"},{"key":"3234_CR57","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3389\/fimmu.2019.01126","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Springfield R, Chen S, Li X, Feng X, Moshirian R, et al. \u03b1-GalCer and iNKT cell-based cancer immunotherapy: realizing the therapeutic potentials. Front Immunol. 2019;10:1126.","journal-title":"Front Immunol"},{"issue":"9","key":"3234_CR58","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20042592","volume":"201","author":"DH Chang","year":"2005","unstructured":"Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201(9):1503\u201317.","journal-title":"J Exp Med"},{"issue":"7","key":"3234_CR59","volume":"16","author":"H Nagai","year":"2024","unstructured":"Nagai H, Chen H, Karube R, Koitabashi Y, Numata O, Yamahara K. Combination of radiation therapy, Wim\u2019s tumor 1 (WT1) dendritic cell vaccine therapy, and \u03b1-galactosylceramide-pulsed dendritic cell vaccine therapy for end-stage small bowel cancer. Cureus. 2024;16(7): e64972.","journal-title":"Cureus"},{"key":"3234_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108597","author":"Y Liu","year":"2024","unstructured":"Liu Y, Dang Y, Zhang C, Liu L, Cai W, Li L, et al. IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. iScience. 2024. https:\/\/doi.org\/10.1016\/j.isci.2023.108597.","journal-title":"iScience"},{"key":"3234_CR61","volume":"73","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhang G. CAR-iNKT cell therapy: Mechanisms, advantages, and challenges. Curr Res Transl Med. 2024;73: 103488.","journal-title":"Curr Res Transl Med"},{"issue":"4","key":"3234_CR62","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/cmi.2017.73","volume":"15","author":"H Chen","year":"2018","unstructured":"Chen H, He W. Human regulatory \u03b3\u03b4T cells and their functional plasticity in the tumor microenvironment. Cell Mol Immunol. 2018;15(4):411\u20133.","journal-title":"Cell Mol Immunol"},{"key":"3234_CR63","first-page":"1","volume":"16","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Niu C, Cui J. Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development? J Transl Med. 2018;16:1\u201313.","journal-title":"J Transl Med"},{"issue":"4","key":"3234_CR64","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo B, Simoes AE, Caiado F, Tieppo P, Correia DV, Carvalho T, et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. Cancer Immunol Res. 2019;7(4):552\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"3234_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1146843","volume":"5","author":"A Benyamine","year":"2016","unstructured":"Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, et al. BTN3A molecules considerably improve V\u03b39V\u03b42T cells-based immunotherapy in acute myeloid leukemia. Oncoimmunology. 2016;5(10): e1146843.","journal-title":"Oncoimmunology"},{"issue":"9","key":"3234_CR66","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","volume":"188","author":"J Gertner-Dardenne","year":"2012","unstructured":"Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, et al. Human V\u03b39V\u03b42 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol. 2012;188(9):4701\u20138.","journal-title":"J Immunol"},{"key":"3234_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00292","volume":"8","author":"M Wieczorek","year":"2017","unstructured":"Wieczorek M, Abualrous ET, Sticht J, \u00c1lvaro-Benito M, Stolzenberg S, No\u00e9 F, Freund C. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017;8: 292.","journal-title":"Front Immunol"},{"key":"3234_CR68","unstructured":"Giannotta C. Untangling the immune suppressive network to accelerate the roadmap for a cure in human myeloma. 2023."},{"key":"3234_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466266","volume":"15","author":"D Zhu","year":"2024","unstructured":"Zhu D, Ren X, Xie W, Chen J, Liang S, Jiang M, et al. Potential of gamma\/delta T cells for solid tumor immunotherapy. Front Immunol. 2024;15: 1466266.","journal-title":"Front Immunol"},{"issue":"6","key":"3234_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267475","volume":"17","author":"X Zhang","year":"2022","unstructured":"Zhang X, Ng YY, Du Z, Li Z, Chen C, Xiao L, et al. V\u03b39V\u03b42 T cells expressing a BCMA-specific chimeric antigen receptor inhibit multiple myeloma xenograft growth. PLoS ONE. 2022;17(6): e0267475.","journal-title":"PLoS ONE"},{"issue":"2","key":"3234_CR71","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00262-022-03260-y","volume":"72","author":"T Ganapathy","year":"2023","unstructured":"Ganapathy T, Radhakrishnan R, Sakshi S, Martin S. CAR \u03b3\u03b4 T cells for cancer immunotherapy. Is the field more yellow than green? Cancer Immunol Immunother. 2023;72(2):277\u201386.","journal-title":"Cancer Immunol Immunother"},{"key":"3234_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007981","author":"A Rao","year":"2024","unstructured":"Rao A, Agrawal A, Borthakur G, Battula VL, Maiti A. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-007981.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"3234_CR73","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","volume":"131","author":"R Handgretinger","year":"2018","unstructured":"Handgretinger R, Schilbach K. The potential role of \u03b3\u03b4 T cells after allogeneic HCT for leukemia. Blood. 2018;131(10):1063\u201372.","journal-title":"Blood"},{"issue":"2","key":"3234_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020146","volume":"13","author":"C Lonez","year":"2024","unstructured":"Lonez C, Breman E. Allogeneic CAR-T therapy technologies: has the promise been met? Cells. 2024;13(2): 146.","journal-title":"Cells"},{"issue":"3","key":"3234_CR75","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3324\/haematol.2010.029520","volume":"96","author":"MS Braza","year":"2010","unstructured":"Braza MS, Klein B, Fiol G, Rossi J-F. \u0393\u03b4 T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica. 2010;96(3):400.","journal-title":"Haematologica"},{"issue":"8","key":"3234_CR76","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","volume":"35","author":"R Ganesan","year":"2021","unstructured":"Ganesan R, Chennupati V, Ramachandran B, Hansen MR, Singh S, Grewal IS. Selective recruitment of \u03b3\u03b4 T cells by a bispecific antibody for the treatment of acute myeloid leukemia. Leukemia. 2021;35(8):2274\u201384.","journal-title":"Leukemia"},{"key":"3234_CR77","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s00262-020-02638-0","volume":"69","author":"Q Guo","year":"2020","unstructured":"Guo Q, Zhao P, Zhang Z, Zhang J, Zhang Z, Hua Y, et al. TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of \u03b3\u03b4 T cells. Cancer Immunol Immunother. 2020;69:2571\u201387.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3234_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00762-6","volume":"13","author":"SG Cieslak","year":"2025","unstructured":"Cieslak SG, Shahbazi R. Gamma delta T cells and their immunotherapeutic potential in cancer. Biomark Res. 2025;13(1): 51.","journal-title":"Biomark Res"},{"issue":"8","key":"3234_CR79","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"4","key":"3234_CR80","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00262-021-03037-9","volume":"71","author":"T Comont","year":"2022","unstructured":"Comont T, Nicolau-Travers ML, Bertoli S, Recher C, Vergez F, Treiner E. MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations. Cancer Immunol Immunother. 2022;71(4):875\u201387.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"3234_CR81","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.3324\/haematol.2017.163758","volume":"102","author":"M Favreau","year":"2017","unstructured":"Favreau M, Venken K, Faict S, Maes K, De Veirman K, De Bruyne E, et al. Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition. Haematologica. 2017;102(7):e266\u201370.","journal-title":"Haematologica"},{"issue":"2","key":"3234_CR82","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/cei.13165","volume":"194","author":"JR Fergusson","year":"2018","unstructured":"Fergusson JR, Ussher JE, Kurioka A, Klenerman P, Walker LJ. High MDR-1 expression by MAIT cells confers resistance to cytotoxic but not immunosuppressive MDR-1 substrates. Clin Exp Immunol. 2018;194(2):180\u201391.","journal-title":"Clin Exp Immunol"},{"key":"3234_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003123","author":"M Tourret","year":"2021","unstructured":"Tourret M, Talvard-Balland N, Lambert M, Ben Youssef G, Chevalier MF, Bohineust A, et al. Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003123.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"3234_CR84","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.4049\/jimmunol.2100856","volume":"209","author":"M Dogan","year":"2022","unstructured":"Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, Unutmaz D. Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy. J Immunol. 2022;209(8):1523\u201331.","journal-title":"J Immunol"},{"key":"3234_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.748741","volume":"12","author":"EM Jarvis","year":"2021","unstructured":"Jarvis EM, Collings S, Authier-Hall A, Dasyam N, Luey B, Nacey J, et al. Mucosal-associated invariant T (MAIT) cell dysfunction and PD-1 expression in prostate cancer: implications for immunotherapy. Front Immunol. 2021;12: 748741.","journal-title":"Front Immunol"},{"key":"3234_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00472","author":"YK Yong","year":"2018","unstructured":"Yong YK, Saeidi A, Tan HY, Rosmawati M, Enstr\u00f6m PF, Batran RA, et al. Hyper-expression of PD-1 is associated with the levels of exhausted and dysfunctional phenotypes of circulating CD161++TCR iV\u03b17.2+ mucosal-associated invariant T cells in chronic hepatitis B virus infection. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.00472.","journal-title":"Front Immunol"},{"key":"3234_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1160943","author":"E Treiner","year":"2023","unstructured":"Treiner E. Mucosal-associated invariant T cells in hematological malignancies: current knowledge, pending questions. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1160943.","journal-title":"Front Immunol"},{"issue":"8","key":"3234_CR88","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/leu.2013.41","volume":"27","author":"S Tan","year":"2013","unstructured":"Tan S, Chuang S, Tang T, Tan L, Ko Y, Chuah K, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8\u03b1\u03b1 phenotype. Leukemia. 2013;27(8):1688\u201396.","journal-title":"Leukemia"},{"issue":"03","key":"3234_CR89","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/BS9.0000000000000194","volume":"6","author":"L Cai","year":"2024","unstructured":"Cai L, Lai W, Yao D, Gu Y, Liang C, Liu L, et al. High percentage of bone marrow CD8+ tissue-resident-like memory T cells predicts inferior survival in patients with acute myeloid leukemia. Blood Sci. 2024;6(03):143\u201352.","journal-title":"Blood Sci"},{"key":"3234_CR90","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fimmu.2017.00316","volume":"8","author":"A Barbarin","year":"2017","unstructured":"Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lef\u00e8vre L, et al. Phenotype of NK-Like CD8(+) T cells with innate features in humans and their relevance in cancer diseases. Front Immunol. 2017;8:316.","journal-title":"Front Immunol"},{"issue":"4","key":"3234_CR91","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood.V99.4.1259","volume":"99","author":"MJ Smyth","year":"2002","unstructured":"Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, et al. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood. 2002;99(4):1259\u201366.","journal-title":"Blood"},{"issue":"10","key":"3234_CR92","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00262-010-0877-2","volume":"59","author":"K Kobayashi","year":"2010","unstructured":"Kobayashi K, Tanaka Y, Horiguchi S, Yamamoto S, Toshinori N, Sugimoto A, Okamoto Y. The effect of radiotherapy on NKT cells in patients with advanced head and neck cancer. Cancer Immunol Immunother. 2010;59(10):1503\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3234_CR93","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1084\/jem.191.4.661","volume":"191","author":"MJ Smyth","year":"2000","unstructured":"Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000;191(4):661\u20138.","journal-title":"J Exp Med"},{"issue":"1","key":"3234_CR94","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4049\/jimmunol.0900873","volume":"183","author":"Y Uemura","year":"2009","unstructured":"Uemura Y, Liu TY, Narita Y, Suzuki M, Nakatsuka R, Araki T, et al. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells. J Immunol. 2009;183(1):201\u20138.","journal-title":"J Immunol"},{"issue":"6","key":"3234_CR95","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ijc.20050","volume":"109","author":"KM Dhodapkar","year":"2004","unstructured":"Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL, Steinman RM. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer. 2004;109(6):893\u20139.","journal-title":"Int J Cancer"},{"issue":"5","key":"3234_CR96","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/2326-6066.CIR-15-0062","volume":"3","author":"RM McEwen-Smith","year":"2015","unstructured":"McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res. 2015;3(5):425\u201335.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"3234_CR97","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020;26(11):1686\u201390.","journal-title":"Nat Med"},{"issue":"6","key":"3234_CR98","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00262-019-02343-7","volume":"68","author":"D Krijgsman","year":"2019","unstructured":"Krijgsman D, de Vries NL, Skovbo A, Andersen MN, Swets M, Bastiaannet E, et al. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. Cancer Immunol Immunother. 2019;68(6):1011\u201324.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"3234_CR99","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.4049\/jimmunol.0803648","volume":"182","author":"VV Parekh","year":"2009","unstructured":"Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, et al. PD-1\/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol. 2009;182(5):2816\u201326.","journal-title":"J Immunol"},{"issue":"6391","key":"3234_CR100","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, et al. Gut microbiome\u2013mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360(6391): eaan5931.","journal-title":"Science"},{"key":"3234_CR101","doi-asserted-by":"crossref","unstructured":"Nater M, Br\u00fcgger MD, Cecconi V, Pereira P, Forni G, K\u00f6ksal H, et al. Hepatic iNKT cells facilitate colorectal cancer metastasis by inducing a fibrotic niche in the liver. bioRxiv. 2024:2024.08.19.608250.","DOI":"10.1101\/2024.08.19.608250"},{"issue":"3","key":"3234_CR102","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.mucimm.2023.03.006","volume":"16","author":"G Lattanzi","year":"2023","unstructured":"Lattanzi G, Strati F, D\u00edaz-Basabe A, Perillo F, Amoroso C, Protti G, et al. iNKT cell-neutrophil crosstalk promotes colorectal cancer pathogenesis. Mucosal Immunol. 2023;16(3):326\u201340.","journal-title":"Mucosal Immunol"},{"issue":"7","key":"3234_CR103","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/biomedicines10071723","volume":"10","author":"JP Loureiro","year":"2022","unstructured":"Loureiro JP, Cruz MS, Cardoso AP, Oliveira MJ, Macedo MF. Human iNKT cells modulate macrophage survival and phenotype. Biomedicines. 2022;10(7):1723.","journal-title":"Biomedicines"},{"key":"3234_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105948","volume":"77","author":"D Chen","year":"2019","unstructured":"Chen D, Zhao H, Gao X, Chen S, Liu H, Zhang J, et al. Subcutaneous administration of \u03b1-GalCer activates iNKT10 cells to promote M2 macrophage polarization and ameliorates chronic inflammation of obese adipose tissue. Int Immunopharmacol. 2019;77: 105948.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3234_CR105","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/mi.2017.34","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Sedimbi S, L\u00f6fbom L, Singh AK, Porcelli SA, Cardell SL. Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells. Mucosal Immunol. 2018;11(1):131\u201343.","journal-title":"Mucosal Immunol"},{"issue":"3","key":"3234_CR106","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado S, Blanco-Dom\u00ednguez R, Silva-Santos B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat Rev Clin Oncol. 2023;20(3):178\u201391.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2\u20133","key":"3234_CR107","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01963.x","volume":"66","author":"P Wrobel","year":"2007","unstructured":"Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol. 2007;66(2\u20133):320\u20138.","journal-title":"Scand J Immunol"},{"issue":"4","key":"3234_CR108","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1158\/2326-6066.CIR-16-0234","volume":"5","author":"J Hu","year":"2017","unstructured":"Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung M-C, et al. Induction of NKG2D ligands on solid tumors requires tumor-specific CD8+ T cells and histone acetyltransferases. Cancer Immunol Res. 2017;5(4):300\u201311.","journal-title":"Cancer Immunol Res"},{"key":"3234_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00992","volume":"11","author":"N Joalland","year":"2020","unstructured":"Joalland N, Scotet E. Emerging challenges of preclinical models of anti-tumor immunotherapeutic strategies utilizing V\u03b39V\u03b42 T cells. Front Immunol. 2020;11: 992.","journal-title":"Front Immunol"},{"issue":"6","key":"3234_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061433","volume":"9","author":"T Herrmann","year":"2020","unstructured":"Herrmann T, Fichtner AS, Karunakaran MM. An update on the molecular basis of phosphoantigen recognition by V\u03b39V\u03b42 T cells. Cells. 2020;9(6): 1433.","journal-title":"Cells"},{"issue":"2","key":"3234_CR111","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/cmi.2013.50","volume":"11","author":"D Kabelitz","year":"2014","unstructured":"Kabelitz D. Critical role of butyrophilin 3A1 in presenting prenyl pyrophosphate antigens to human \u03b3\u03b4 T cells. Cell Mol Immunol. 2014;11(2):117\u20139.","journal-title":"Cell Mol Immunol"},{"key":"3234_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876493","volume":"13","author":"T Herrmann","year":"2022","unstructured":"Herrmann T, Karunakaran MM. Butyrophilins: \u03b3\u03b4 T cell receptor ligands, immunomodulators and more. Front Immunol. 2022;13: 876493.","journal-title":"Front Immunol"},{"issue":"8","key":"3234_CR113","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.it.2021.06.002","volume":"42","author":"M Rigau","year":"2021","unstructured":"Rigau M, Uldrich AP, Behren A. Targeting butyrophilins for cancer immunotherapy. Trends Immunol. 2021;42(8):670\u201380.","journal-title":"Trends Immunol"},{"key":"3234_CR114","doi-asserted-by":"publisher","first-page":"1140623","DOI":"10.3389\/fimmu.2023.1140623","volume":"14","author":"L Ma","year":"2023","unstructured":"Ma L, Feng Y, Zhou Z. A close look at current \u03b3\u03b4 T-cell immunotherapy. Front Immunol. 2023;14:1140623.","journal-title":"Front Immunol"},{"issue":"10","key":"3234_CR115","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.3390\/cancers15102752","volume":"15","author":"JM Pimentel","year":"2023","unstructured":"Pimentel JM, Zhou J-Y, Wu GS. The role of TRAIL in apoptosis and immunosurveillance in cancer. Cancers. 2023;15(10):2752.","journal-title":"Cancers"},{"key":"3234_CR116","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-030-49270-0_5","volume-title":"Tumor microenvironment: hematopoietic cells part B","author":"C Imbert","year":"2020","unstructured":"Imbert C, Olive D. \u03b3\u03b4 T cells in tumor microenvironment. In: Birbrair A, editor. Tumor microenvironment: hematopoietic cells part B. Cham: Springer; 2020. p. 91\u2013104."},{"key":"3234_CR117","doi-asserted-by":"publisher","first-page":"1077419","DOI":"10.3389\/fgene.2022.1077419","volume":"13","author":"R Zhu","year":"2023","unstructured":"Zhu R, Yan Q, Wang Y, Wang K. Biological characteristics of \u03b3\u03b4T cells and application in tumor immunotherapy. Front Genet. 2023;13:1077419.","journal-title":"Front Genet"},{"key":"3234_CR118","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211431","author":"SC Edwards","year":"2023","unstructured":"Edwards SC, Hedley A, Hoevenaar WH, Wiesheu R, Glauner T, Kilbey A, et al. PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A\u2013producing \u03b3\u03b4 T cells. J Exp Med. 2023. https:\/\/doi.org\/10.1084\/jem.20211431.","journal-title":"J Exp Med"},{"key":"3234_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699478","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Yang C, Li L, Zhu Y, Su K, Zhai L, et al. \u0393\u03b4t cell-IL17A-neutrophil axis drives immunosuppression and confers breast cancer resistance to high-dose anti-VEGFR2 therapy. Front Immunol. 2021;12: 699478.","journal-title":"Front Immunol"},{"issue":"4","key":"3234_CR120","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/onco4040019","volume":"4","author":"C Guernsey-Biddle","year":"2024","unstructured":"Guernsey-Biddle C, High P, Carmon KS. Exploring the potential of epiregulin and amphiregulin as prognostic, predictive, and therapeutic targets in colorectal cancer. Onco. 2024;4(4):257\u201374.","journal-title":"Onco"},{"issue":"692","key":"3234_CR121","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abc5884","volume":"14","author":"N Sumaria","year":"2021","unstructured":"Sumaria N, Martin S, Pennington DJ. Constrained TCR\u03b3\u03b4-associated Syk activity engages PI3K to facilitate thymic development of IL-17A\u2013secreting \u03b3\u03b4 T cells. Sci Signal. 2021;14(692): eabc5884.","journal-title":"Sci Signal"},{"issue":"8","key":"3234_CR122","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02434-1","volume":"41","author":"D \u0141aszczych","year":"2024","unstructured":"\u0141aszczych D, Czernicka A, Gostomczyk K, Szylberg \u0141, Borowczak J. The role of IL-17 in the pathogenesis and treatment of glioblastoma\u2014an update on the state of the art and future perspectives. Med Oncol. 2024;41(8): 187.","journal-title":"Med Oncol"},{"issue":"1","key":"3234_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51025-1","volume":"15","author":"V Stary","year":"2024","unstructured":"Stary V, Pandey RV, List J, Kleissl L, Deckert F, Kabiljo J, et al. Dysfunctional tumor-infiltrating V\u03b41+ T lymphocytes in microsatellite-stable colorectal cancer. Nat Commun. 2024;15(1): 6949.","journal-title":"Nat Commun"},{"issue":"4","key":"3234_CR124","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41590-023-01448-7","volume":"24","author":"C Rancan","year":"2023","unstructured":"Rancan C, Arias-Badia M, Dogra P, Chen B, Aran D, Yang H, et al. Exhausted intratumoral V\u03b42\u2212 \u03b3\u03b4 T cells in human kidney cancer retain effector function. Nat Immunol. 2023;24(4):612\u201324.","journal-title":"Nat Immunol"},{"issue":"7","key":"3234_CR125","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","volume":"12","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers. 2020;12(7):1760.","journal-title":"Cancers"},{"issue":"9","key":"3234_CR126","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","volume":"17","author":"D Kabelitz","year":"2020","unstructured":"Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us. Cell Mol Immunol. 2020;17(9):925\u201339.","journal-title":"Cell Mol Immunol"},{"key":"3234_CR127","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001185","author":"K Kakimi","year":"2020","unstructured":"Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, et al. Adoptive transfer of zoledronate-expanded autologous V\u03b39V\u03b42 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001185.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3234_CR128","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ejcts.2009.11.051","volume":"37","author":"J Nakajima","year":"2010","unstructured":"Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg. 2010;37(5):1191\u20137.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"3234_CR129","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jcyt.2012.12.004","volume":"15","author":"T Izumi","year":"2013","unstructured":"Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, et al. Ex vivo characterization of \u03b3\u03b4 T-cell repertoire in patients after adoptive transfer of V\u03b39V\u03b42 T cells expressing the interleukin-2 receptor \u03b2-chain and the common \u03b3-chain. Cytotherapy. 2013;15(4):481\u201391.","journal-title":"Cytotherapy"},{"issue":"3","key":"3234_CR130","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ymthe.2022.11.019","volume":"31","author":"Y-R Li","year":"2023","unstructured":"Li Y-R, Zhou K, Wilson M, Kramer A, Zhu Y, Dawson N, Yang L. Mucosal-associated invariant T cells for cancer immunotherapy. Mol Ther. 2023;31(3):631\u201346.","journal-title":"Mol Ther"},{"issue":"12","key":"3234_CR131","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00262-018-2132-1","volume":"67","author":"SMM Haeryfar","year":"2018","unstructured":"Haeryfar SMM, Shaler CR, Rudak PT. Mucosa-associated invariant T cells in malignancies: a faithful friend or formidable foe? Cancer Immunol Immunother. 2018;67(12):1885\u201396.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"3234_CR132","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.4049\/jimmunol.1500258","volume":"195","author":"P Sundstr\u00f6m","year":"2015","unstructured":"Sundstr\u00f6m P, Ahlmanner F, Ak\u00e9us P, Sundquist M, Als\u00e9n S, Yrlid U, et al. Human mucosa-associated invariant T cells accumulate in colon adenocarcinomas but produce reduced amounts of IFN-\u03b3. J Immunol. 2015;195(7):3472\u201381.","journal-title":"J Immunol"},{"key":"3234_CR133","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00262-015-1764-7","volume":"64","author":"L Zabijak","year":"2015","unstructured":"Zabijak L, Attencourt C, Guignant C, Chatelain D, Marcelo P, Marolleau J-P, Treiner E. Increased tumor infiltration by mucosal-associated invariant T cells correlates with poor survival in colorectal cancer patients. Cancer Immunol Immunother. 2015;64:1601\u20138.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3234_CR134","doi-asserted-by":"publisher","first-page":"20358","DOI":"10.1038\/srep20358","volume":"6","author":"L Ling","year":"2016","unstructured":"Ling L, Lin Y, Zheng W, Hong S, Tang X, Zhao P, et al. Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients. Sci Rep. 2016;6(1):20358.","journal-title":"Sci Rep"},{"issue":"46","key":"3234_CR135","doi-asserted-by":"publisher","first-page":"76274","DOI":"10.18632\/oncotarget.11187","volume":"7","author":"EJ Won","year":"2016","unstructured":"Won EJ, Ju JK, Cho Y-N, Jin H-M, Park K-J, Kim T-J, et al. Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer. Oncotarget. 2016;7(46):76274.","journal-title":"Oncotarget"},{"issue":"1","key":"3234_CR136","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.tjog.2018.11.022","volume":"58","author":"W-C Huang","year":"2019","unstructured":"Huang W-C, Hsiao Y-C, Wu C-C, Hsu Y-T, Chang C-L. Less circulating mucosal-associated invariant T cells in patients with cervical cancer. Taiwan J Obstet Gynecol. 2019;58(1):117\u201321.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"8","key":"3234_CR137","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/imcb.12281","volume":"97","author":"J Kelly","year":"2019","unstructured":"Kelly J, Minoda Y, Meredith T, Cameron G, Philipp MS, Pellicci DG, et al. Chronically stimulated human MAIT cells are unexpectedly potent IL-13 producers. Immunol Cell Biol. 2019;97(8):689\u201399.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"3234_CR138","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2159-8290.CD-19-0569","volume":"10","author":"J Yan","year":"2020","unstructured":"Yan J, Allen S, McDonald E, Das I, Mak JY, Liu L, et al. MAIT cells promote tumor initiation, growth, and metastases via tumor MR1. Cancer Discov. 2020;10(1):124\u201341.","journal-title":"Cancer Discov"},{"issue":"29","key":"3234_CR139","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.18632\/oncotarget.26866","volume":"10","author":"P Sundstr\u00f6m","year":"2019","unstructured":"Sundstr\u00f6m P, Szeponik L, Ahlmanner F, Sundquist M, Wong JS, Lindskog EB, et al. Tumor-infiltrating mucosal-associated invariant T (MAIT) cells retain expression of cytotoxic effector molecules. Oncotarget. 2019;10(29):2810.","journal-title":"Oncotarget"},{"key":"3234_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00949","volume":"11","author":"SP Berzins","year":"2020","unstructured":"Berzins SP, Wallace ME, Kannourakis G, Kelly J. A role for MAIT cells in colorectal cancer. Front Immunol. 2020;11: 949.","journal-title":"Front Immunol"},{"issue":"5","key":"3234_CR141","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.7150\/jca.69415","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Li P, Zhou W, Fang S, Wang J. Participation of increased circulating MAIT cells in lung cancer: a pilot study. J Cancer. 2022;13(5):1623\u20139.","journal-title":"J Cancer"},{"key":"3234_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410241","author":"P Niekamp","year":"2025","unstructured":"Niekamp P, Kim RH, Jayaraman A, Klement N, Kostlan R, Kim CH. The nuclear receptor NR1B1\/RAR\u03b1 arrests the differentiation of anti-tumor effector cytotoxic T cells. Adv Sci. 2025. https:\/\/doi.org\/10.1002\/advs.202410241.","journal-title":"Adv Sci"},{"issue":"1","key":"3234_CR143","doi-asserted-by":"publisher","first-page":"10877","DOI":"10.1038\/s41598-019-47381-4","volume":"9","author":"CL Fischer","year":"2019","unstructured":"Fischer CL, Bates AM, Lanzel EA, Guthmiller JM, Johnson GK, Singh NK, et al. Computational models accurately predict multi-cell biomarker profiles in inflammation and cancer. Sci Rep. 2019;9(1):10877.","journal-title":"Sci Rep"},{"key":"3234_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.850731","volume":"12","author":"A Uthamacumaran","year":"2022","unstructured":"Uthamacumaran A, Zenil H. A review of mathematical and computational methods in cancer dynamics. Front Oncol. 2022;12: 850731.","journal-title":"Front Oncol"},{"issue":"5","key":"3234_CR145","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3390\/ijms23052805","volume":"23","author":"B Smolarz","year":"2022","unstructured":"Smolarz B, Durczy\u0144ski A, Romanowicz H, Szy\u0142\u0142o K, Hogendorf P. miRNAs in cancer (review of literature). Int J Mol Sci. 2022;23(5):2805.","journal-title":"Int J Mol Sci"},{"key":"3234_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15155","author":"W Pan","year":"2023","unstructured":"Pan W, Chai B, Li L, Lu Z, Ma Z. P53\/MicroRNA-34 axis in cancer and beyond. Heliyon. 2023. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15155.","journal-title":"Heliyon"},{"issue":"2","key":"3234_CR147","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.gene.2015.06.046","volume":"570","author":"X Wang","year":"2015","unstructured":"Wang X, Zheng G, Dong D. Coordinated action of histone modification and microRNA regulations in human genome. Gene. 2015;570(2):277\u201381.","journal-title":"Gene"},{"key":"3234_CR148","first-page":"1","volume-title":"MiRNomics: MicroRNA biology and computational analysis","author":"K Ergin","year":"2022","unstructured":"Ergin K, \u00c7etinkaya R. Regulation of microRNAs. In: Allmer J, Yousef M, editors. MiRNomics: MicroRNA biology and computational analysis. New York: Humana; 2022. p. 1\u201332."},{"key":"3234_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O'Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9: 402.","journal-title":"Front Endocrinol"},{"issue":"3","key":"3234_CR150","first-page":"289","volume":"19","author":"N Arghiani","year":"2021","unstructured":"Arghiani N, Shah K. Modulating micrornas in cancer: next-generation therapies. Cancer Biol Med. 2021;19(3):289\u2013304.","journal-title":"Cancer Biol Med"},{"key":"3234_CR151","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/978-1-0716-1170-8_18","volume-title":"miRNomics: MicroRNA biology and computational analysis","author":"E Uzuner","year":"2022","unstructured":"Uzuner E, Ulu GT, G\u00fcrler SB, Baran Y. The role of MiRNA in cancer: pathogenesis, diagnosis, and treatment. In: Allmer J, Yousef M, editors. miRNomics: MicroRNA biology and computational analysis. Humana: New York; 2022. p. 375\u2013422."},{"issue":"12","key":"3234_CR152","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/cbin.12243","volume":"48","author":"R Susanti","year":"2024","unstructured":"Susanti R, Dafip M, Mustikaningtyas D, Putra A. Predictive action of oncomiR in suppressing TP53 signaling pathway in hypoxia-conditioned colon cancer cell line HCT-116. Cell Biol Int. 2024;48(12):1891\u2013905.","journal-title":"Cell Biol Int"},{"key":"3234_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708765","volume":"11","author":"K Otmani","year":"2021","unstructured":"Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11: 708765.","journal-title":"Front Oncol"},{"key":"3234_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116165","volume":"171","author":"K Otmani","year":"2024","unstructured":"Otmani K, Rouas R, Berehab M, Lewalle P. The regulatory mechanisms of oncomirs in cancer. Biomed Pharmacother. 2024;171: 116165.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3234_CR155","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13353-023-00750-2","volume":"64","author":"M Frydrychowicz","year":"2023","unstructured":"Frydrychowicz M, Kuszel \u0141, Dworacki G, Budna-Tukan J. Microrna in lung cancer-a novel potential way for early diagnosis and therapy. J Appl Genet. 2023;64(3):459\u201377.","journal-title":"J Appl Genet"},{"issue":"4","key":"3234_CR156","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/mc.23167","volume":"59","author":"LW Yang","year":"2020","unstructured":"Yang LW, Wu XJ, Liang Y, Ye GQ, Che Y, Wu XZ, et al. Mir-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5. Mol Carcinog. 2020;59(4):447\u201361.","journal-title":"Mol Carcinog"},{"issue":"4","key":"3234_CR157","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3390\/ijms25042167","volume":"25","author":"C Belnap","year":"2024","unstructured":"Belnap C, Divis T, Kingsley K, Howard KM. Differential expression of microRNA miR-145 and miR-155 downstream targets in oral cancers exhibiting limited chemotherapy resistance. Int J Mol Sci. 2024;25(4):2167.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3234_CR158","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1158\/1078-0432.CCR-16-1025","volume":"23","author":"K Van Roosbroeck","year":"2017","unstructured":"Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Vannini I, et al. A miR-155\/TP53 regulatory feedback loop involved in resistance to therapy in lung cancer and leukemia. Clin Cancer Res. 2017;23(11):2891.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3234_CR159","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/glia.23988","volume":"69","author":"MS Aloi","year":"2021","unstructured":"Aloi MS, Prater KE, Sopher B, Davidson S, Jayadev S, Garden GA. The pro-inflammatory microRNA miR-155 influences fibrillar \u03b2-amyloid1-42 catabolism by microglia. Glia. 2021;69(7):1736\u201348.","journal-title":"Glia"},{"issue":"1","key":"3234_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40001-025-02618-z","volume":"30","author":"QM Hussain","year":"2025","unstructured":"Hussain QM, Al-Hussainy AF, Sanghvi G, Roopashree R, Kashyap A, Anand DA, et al. Dual role of miR-155 and exosomal miR-155 in tumor angiogenesis: implications for cancer progression and therapy. Eur J Med Res. 2025;30(1):1\u201314.","journal-title":"Eur J Med Res"},{"issue":"6","key":"3234_CR161","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1158\/2326-6066.CIR-18-0504","volume":"7","author":"A Martinez-Usatorre","year":"2019","unstructured":"Martinez-Usatorre A, Sempere LF, Carmona SJ, Carretero-Iglesia L, Monnot G, Speiser DE, et al. Microrna-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in melanoma. Cancer Immunol Res. 2019;7(6):1013\u201324.","journal-title":"Cancer Immunol Res"},{"key":"3234_CR162","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2147\/CMAR.S232388","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zeng G, Jiang Y. The emerging roles of miR-125b in cancers. Cancer Manag Res. 2020;12:1079\u201388.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"3234_CR163","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/cmi.2017.164","volume":"16","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Zhang S, Li Z, Wang H, Li Z, Hu Y, et al. Mir-125b-5p and mir-99a-5p downregulate human \u03b3\u03b4 T-cell activation and cytotoxicity. Cell Mol Immunol. 2019;16(2):112\u201325.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"3234_CR164","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1038\/bjc.2013.672","volume":"109","author":"N Wu","year":"2013","unstructured":"Wu N, Lin X, Zhao X, Zheng L, Xiao L, Liu J, et al. MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways. Br J Cancer. 2013;109(11):2853\u201363.","journal-title":"Br J Cancer"},{"issue":"3","key":"3234_CR165","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.leukres.2013.12.021","volume":"38","author":"ML Ufkin","year":"2014","unstructured":"Ufkin ML, Peterson S, Yang X, Driscoll H, Duarte C, Sathyanarayana P. Mir-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res. 2014;38(3):402\u201310.","journal-title":"Leuk Res"},{"issue":"5","key":"3234_CR166","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1541-7786.MCR-20-0973","volume":"19","author":"AY Kam","year":"2021","unstructured":"Kam AY, Piryani SO, Lee C-L, Rizzieri DA, Spector NL, Sarantopoulos S, Doan PL. Selective ERBB2 and BCL2 inhibition is synergistic for mitochondrial-mediated apoptosis in MDS and AML cells. Mol Cancer Res. 2021;19(5):886\u201399.","journal-title":"Mol Cancer Res"},{"issue":"12","key":"3234_CR167","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190193","volume":"39","author":"M Yang","year":"2019","unstructured":"Yang M, Tang X, Wang Z, Wu X, Tang D, Wang D. miR-125 inhibits colorectal cancer proliferation and invasion by targeting TAZ. Biosci Rep. 2019;39(12): BSR20190193.","journal-title":"Biosci Rep"},{"issue":"1","key":"3234_CR168","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1038\/s41467-018-05552-3","volume":"9","author":"Z Ye","year":"2018","unstructured":"Ye Z, Li G, Kim C, Hu B, Jadhav RR, Weyand CM, Goronzy JJ. Regulation of miR-181a expression in T cell aging. Nat Commun. 2018;9(1):3060.","journal-title":"Nat Commun"},{"issue":"1","key":"3234_CR169","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12935-023-03105-3","volume":"23","author":"A Ameri","year":"2023","unstructured":"Ameri A, Ahmed HM, Pecho RDC, Arabnozari H, Sarabadani H, Esbati R, et al. Diverse activity of miR-150 in tumor development: shedding light on the potential mechanisms. Cancer Cell Int. 2023;23(1):261.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"3234_CR170","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ejca.2013.12.024","volume":"50","author":"M Cao","year":"2014","unstructured":"Cao M, Hou D, Liang H, Gong F, Wang Y, Yan X, et al. Mir-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer. 2014;50(5):1013\u201324.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3234_CR171","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jaci.2014.02.018","volume":"134","author":"N Kim","year":"2014","unstructured":"Kim N, Kim M, Yun S, Doh J, Greenberg PD, Kim T-D, Choi I. Microrna-150 regulates the cytotoxicity of natural killers by targeting perforin-1. J Allergy Clin Immunol. 2014;134(1):195-203.e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"15","key":"3234_CR172","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/s41388-018-0627-z","volume":"38","author":"L Li","year":"2019","unstructured":"Li L, Cao B, Liang X, Lu S, Luo H, Wang Z, et al. Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral \u03b3\u03b4 T cell equilibrium via tumor-derived exosomes. Oncogene. 2019;38(15):2830\u201343.","journal-title":"Oncogene"},{"issue":"5","key":"3234_CR173","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/ar.23763","volume":"301","author":"S Shyamasundar","year":"2018","unstructured":"Shyamasundar S, Ong C, Yung LL, Dheen ST, Bay BH. miR-128 regulates genes associated with inflammation and fibrosis of rat kidney cells in vitro. Anat Rec. 2018;301(5):913\u201321.","journal-title":"Anat Rec"},{"issue":"5","key":"3234_CR174","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1002\/jcp.27342","volume":"234","author":"T Liu","year":"2019","unstructured":"Liu T, Xu Z, Ou D, Liu J, Zhang J. The miR-15a\/16 gene cluster in human cancer: a systematic review. J Cell Physiol. 2019;234(5):5496\u2013506.","journal-title":"J Cell Physiol"},{"key":"3234_CR175","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180441","author":"H Yao","year":"2019","unstructured":"Yao H, Xia D, Li ZL, Ren L, Wang MM, Chen WS, et al. MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer. 2019. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20180441."},{"issue":"1","key":"3234_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02084-x","volume":"23","author":"X Yu","year":"2024","unstructured":"Yu X, Zhang Y, Luo F, Zhou Q, Zhu L. The role of microRNAs in the gastric cancer tumor microenvironment. Mol Cancer. 2024;23(1): 170.","journal-title":"Mol Cancer"},{"issue":"5","key":"3234_CR177","first-page":"4053","volume":"14","author":"H Yu","year":"2017","unstructured":"Yu H, Xu W, Gong F, Chi B, Chen J, Zhou L. Microrna-155 regulates the proliferation, cell cycle, apoptosis and migration of colon cancer cells and targets CBL. Exp Ther Med. 2017;14(5):4053\u201360.","journal-title":"Exp Ther Med"},{"issue":"4","key":"3234_CR178","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2012.12.006","volume":"38","author":"JC Dudda","year":"2013","unstructured":"Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, et al. Microrna-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity. 2013;38(4):742\u201353.","journal-title":"Immunity"},{"issue":"12","key":"3234_CR179","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1002\/eji.200737830","volume":"38","author":"S Vallabhapurapu","year":"2008","unstructured":"Vallabhapurapu S, Powolny-Budnicka I, Riemann M, Schmid RM, Paxian S, Pfeffer K, et al. Rel\/NF-\u03baB family member RelA regulates NK1. 1\u2212 to NK1. 1+ transition as well as IL-15-induced expansion of NKT cells. Eur J Immunol. 2008;38(12):3508\u201319.","journal-title":"Eur J Immunol"},{"issue":"24","key":"3234_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246211","volume":"13","author":"JC Hoffmann","year":"2021","unstructured":"Hoffmann JC, Sch\u00f6n MP. Integrin \u03b1E (CD103) \u03b27 in epithelial cancer. Cancers (Basel). 2021;13(24): 6211.","journal-title":"Cancers (Basel)"},{"key":"3234_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02520","volume":"10","author":"SJ Winter","year":"2019","unstructured":"Winter SJ, Krueger A. Development of unconventional T cells controlled by microRNA. Front Immunol. 2019;10: 2520.","journal-title":"Front Immunol"},{"issue":"1","key":"3234_CR182","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s40425-019-0670-5","volume":"7","author":"M Hart","year":"2019","unstructured":"Hart M, Walch-R\u00fcckheim B, Krammes L, Kehl T, Rheinheimer S, T\u00e4nzer T, et al. miR-34a as hub of T cell regulation networks. J Immunother Cancer. 2019;7(1):187.","journal-title":"J Immunother Cancer"},{"key":"3234_CR183","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1390704","volume":"12","author":"AS Abdul Manap","year":"2024","unstructured":"Abdul Manap AS, Wisham AA, Wong FW, Ahmad Najmi HR, Ng ZF, Diba RS. Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies. Front Cell Dev Biol. 2024;12: 1390704.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"3234_CR184","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/ni.3146","volume":"16","author":"LA Pobezinsky","year":"2015","unstructured":"Pobezinsky LA, Etzensperger R, Jeurling S, Alag A, Kadakia T, McCaughtry TM, et al. Let-7 microRNAs target the lineage-specific transcription factor PLZF to regulate terminal NKT cell differentiation and effector function. Nat Immunol. 2015;16(5):517\u201324.","journal-title":"Nat Immunol"},{"issue":"22","key":"3234_CR185","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.3748\/wjg.v21.i22.6884","volume":"21","author":"B Qi","year":"2015","unstructured":"Qi B, Lu J-G, Yao W-J, Chang T-M, Qin X-G, Ji Y-H, et al. Downregulation of microRNA-382 is associated with poor outcome of esophageal squamous cell carcinoma. World J Gastroenterol WJG. 2015;21(22):6884.","journal-title":"World J Gastroenterol WJG"},{"issue":"3","key":"3234_CR186","doi-asserted-by":"publisher","first-page":"G309","DOI":"10.1152\/ajpgi.00322.2019","volume":"319","author":"X Wan","year":"2020","unstructured":"Wan X, Guo D, Zhu Q, Qu R. microRNA-382 suppresses the progression of pancreatic cancer through the PI3K\/Akt signaling pathway by inhibition of Anxa3. Am J Physiol-Gastrointest Liver Physiol. 2020;319(3):G309\u201322.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3234_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00890","author":"Q Xi","year":"2020","unstructured":"Xi Q, Chen Y, Yang G-Z, Zhang J-Y, Zhang L-J, Guo X-D, et al. MiR-128 regulates tumor cell CD47 expression and promotes anti-tumor immunity in pancreatic cancer. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00890.","journal-title":"Front Immunol"},{"issue":"4","key":"3234_CR188","first-page":"187","volume":"33","author":"RN Ragab","year":"2024","unstructured":"Ragab RN, El-Shimi OS, Zakaria RM, Khalil AE, Anwer MM, Abdelrahman SM, et al. Immune-related miRNAs (181a, 146, 150) expression in colostrum and mature maternal milk in normally and caesarean delivered females. Egypt J Med Microbiol. 2024;33(4):187\u201393.","journal-title":"Egypt J Med Microbiol"},{"issue":"3","key":"3234_CR189","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/eji.201746921","volume":"47","author":"M Verykokakis","year":"2017","unstructured":"Verykokakis M, Kee BL. Applying the TOR (C) QUE in iNKT cells: a new twist in an old tale. Eur J Immunol. 2017;47(3):454\u20137.","journal-title":"Eur J Immunol"},{"issue":"28","key":"3234_CR190","doi-asserted-by":"publisher","first-page":"24599","DOI":"10.18632\/oncotarget.5248","volume":"6","author":"E Tili","year":"2015","unstructured":"Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, et al. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget. 2015;6(28):24599\u2013610.","journal-title":"Oncotarget"},{"issue":"19","key":"3234_CR191","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157248","volume":"132","author":"J Wang","year":"2022","unstructured":"Wang J, Wang Q, Guan Y, Sun Y, Wang X, Lively K, et al. Breast cancer cell\u2013derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. J Clin Investig. 2022;132(19): e157248.","journal-title":"J Clin Investig"},{"issue":"8","key":"3234_CR192","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/s41423-021-00711-x","volume":"18","author":"H Chen","year":"2021","unstructured":"Chen H, Zhang J, He W. The role of microRNAs in \u03b3\u03b4 T cells: a long way to go. Cell Mol Immunol. 2021;18(8):2071\u20132.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"3234_CR193","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s12276-021-00576-0","volume":"53","author":"JH Park","year":"2021","unstructured":"Park JH, Lee HK. Function of \u03b3\u03b4 T cells in tumor immunology and their application to cancer therapy. Exp Mol Med. 2021;53(3):318\u201327.","journal-title":"Exp Mol Med"},{"issue":"2","key":"3234_CR194","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1073\/pnas.1422916112","volume":"112","author":"Y Ji","year":"2015","unstructured":"Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk NV, et al. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic \u03b3c cytokines. Proc Natl Acad Sci. 2015;112(2):476\u201381.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"3234_CR195","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.jaci.2017.07.019","volume":"141","author":"S-H Seo","year":"2018","unstructured":"Seo S-H, Jang MS, Kim D-J, Kim S-M, Oh S-C, Jung C-R, et al. MicroRNA-150 controls differentiation of intraepithelial lymphocytes through TGF-\u03b2 receptor II regulation. J Allergy Clin Immunol. 2018;141(4):1382-94.e14.","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"3234_CR196","doi-asserted-by":"publisher","first-page":"12839","DOI":"10.3390\/ijms252312839","volume":"25","author":"I Sergio","year":"2024","unstructured":"Sergio I, Varricchio C, Squillante F, Cantale Aeo NM, Campese AF, Felli MP. Notch inhibitors and BH3 mimetics in T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2024;25(23):12839.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3234_CR197","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.4049\/jimmunol.1103342","volume":"188","author":"Q Zheng","year":"2012","unstructured":"Zheng Q, Zhou L, Mi QS. Microrna miR-150 is involved in V\u03b114 invariant NKT cell development and function. J Immunol. 2012;188(5):2118\u201326.","journal-title":"J Immunol"},{"issue":"5","key":"3234_CR198","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13025","volume":"93","author":"E Dybska","year":"2021","unstructured":"Dybska E, Adams AT, Duclaux-Loras R, Walkowiak J, Nowak JK. Waiting in the wings: RUNX3 reveals hidden depths of immune regulation with potential implications for inflammatory bowel disease. Scand J Immunol. 2021;93(5): e13025.","journal-title":"Scand J Immunol"},{"issue":"1","key":"3234_CR199","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cell.2007.03.008","volume":"129","author":"QJ Li","year":"2007","unstructured":"Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007;129(1):147\u201361.","journal-title":"Cell"},{"issue":"17","key":"3234_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176200","volume":"21","author":"Z Grewers","year":"2020","unstructured":"Grewers Z, Krueger A. MicroRNA miR-181\u2014a rheostat for TCR signaling in thymic selection and peripheral T-cell function. Int J Mol Sci. 2020;21(17): 6200.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3234_CR201","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145010","volume":"10","author":"I Sandrock","year":"2015","unstructured":"Sandrock I, Zi\u0119tara N, \u0141yszkiewicz M, Oberd\u00f6rfer L, Witzlau K, Krueger A, Prinz I. Microrna-181a\/b-1 is not required for innate \u03b3\u03b4 NKT effector cell development. PLoS ONE. 2015;10(12): e0145010.","journal-title":"PLoS ONE"},{"key":"3234_CR202","unstructured":"T\u00fcrkal M. Attenuating inflammation by modulation Microrna-155 expression in macrophages using lipid nanoparticles and extracellular vesicles. University of Twente; 2022."},{"issue":"3","key":"3234_CR203","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jconrel.2013.03.020","volume":"168","author":"M Zhang","year":"2013","unstructured":"Zhang M, Zhou X, Wang B, Yung BC, Lee LJ, Ghoshal K, Lee RJ. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release. 2013;168(3):251\u201361.","journal-title":"J Control Release"},{"issue":"4","key":"3234_CR204","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat Nanotechnol. 2020;15(4):313\u201320.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"3234_CR205","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/eji.200939381","volume":"40","author":"A Banerjee","year":"2010","unstructured":"Banerjee A, Schambach F, DeJong CS, Hammond SM, Reiner SL. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol. 2010;40(1):225\u201331.","journal-title":"Eur J Immunol"},{"issue":"1","key":"3234_CR206","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1166\/mex.2022.2134","volume":"12","author":"H Yu","year":"2022","unstructured":"Yu H, Shi M, Sun J, Yuan H. Liposomal nanoparticle-based miR-155 antagonist regulates Th17\/Treg signaling pathway and its inhibitory effect against myocarditis. Mater Express. 2022;12(1):49\u201356.","journal-title":"Mater Express"},{"key":"3234_CR207","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228458","volume":"14","author":"A Farhana","year":"2023","unstructured":"Farhana A, Alsrhani A, Rasheed N, Rasheed Z. Gold nanoparticles attenuate the interferon-\u03b3 induced SOCS1 expression and activation of NF-\u03baB p65\/50 activity via modulation of microRNA-155-5p in triple-negative breast cancer cells. Front Immunol. 2023;14: 1228458.","journal-title":"Front Immunol"},{"issue":"1","key":"3234_CR208","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01341-4","volume":"16","author":"DJ Merk","year":"2024","unstructured":"Merk DJ, Paul L, Tsiami F, Hohenthanner H, Kouchesfahani GM, Haeusser LA, et al. CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines. Genome Med. 2024;16(1): 82.","journal-title":"Genome Med"},{"issue":"49","key":"3234_CR209","doi-asserted-by":"publisher","first-page":"E11513","DOI":"10.1073\/pnas.1812273115","volume":"115","author":"J Dias","year":"2018","unstructured":"Dias J, Boulouis C, Gorin JB, van den Biggelaar R, Lal KG, Gibbs A, et al. The CD4(-)CD8(-) MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8(+) MAIT cell pool. Proc Natl Acad Sci USA. 2018;115(49):E11513\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"3234_CR210","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41577-019-0191-y","volume":"19","author":"A Toubal","year":"2019","unstructured":"Toubal A, Nel I, Lotersztajn S, Lehuen A. Mucosal-associated invariant T cells and disease. Nat Rev Immunol. 2019;19(10):643\u201357.","journal-title":"Nat Rev Immunol"},{"key":"3234_CR211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","volume":"11","author":"Q Huang","year":"2018","unstructured":"Huang Q, Xia J, Wang L, Wang X, Ma X, Deng Q, et al. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. J Hematol Oncol. 2018;11:1\u201312.","journal-title":"J Hematol Oncol"},{"key":"3234_CR212","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.673286","volume":"12","author":"L Duan","year":"2021","unstructured":"Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X, et al. Nanoparticle delivery of CRISPR\/Cas9 for genome editing. Front Genet. 2021;12: 673286.","journal-title":"Front Genet"},{"key":"3234_CR213","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0315","author":"A Urakami","year":"2023","unstructured":"Urakami A, Shioya K, Shigeura T, Matsumura T, Mishima Y, Okoshi M, et al. 315 iPSC-derived CAR-iNKT cells targeting HER2 show prolonged tumor control and promote durable survival in a tumor xenograft model. BMJ Spec J. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0315.","journal-title":"BMJ Spec J"},{"issue":"4","key":"3234_CR214","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/nar\/gkae003","volume":"52","author":"AF Buhagiar","year":"2024","unstructured":"Buhagiar AF, Kleaveland B. To kill a microRNA: emerging concepts in target-directed microRNA degradation. Nucleic Acids Res. 2024;52(4):1558\u201374.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3234_CR215","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","volume":"44","author":"MTD Martino","year":"2025","unstructured":"Martino MTD, Tagliaferri P, Tassone P. Microrna in cancer therapy: breakthroughs and challenges in early clinical applications. J Exp Clin Cancer Res. 2025;44(1):126.","journal-title":"J Exp Clin Cancer Res"},{"key":"3234_CR216","doi-asserted-by":"crossref","unstructured":"Aram, C et al. Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches. Biochemistry and Biophysics Reports 39 (2024):101745","DOI":"10.1016\/j.bbrep.2024.101745"},{"key":"3234_CR217","doi-asserted-by":"crossref","unstructured":"Saleki K, Aram C, Alijanizadeh P, Khanmirzaei MH, Vaziri Z, Ramzankhah M, Azadmehr A. Matrix metalloproteinase\/Fas ligand (MMP\/FasL) interaction dynamics in COVID-19: An in silico study and neuroimmune perspective. Heliyon. 2024;30;10(10).","DOI":"10.1016\/j.heliyon.2024.e30898"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03234-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:19:27Z","timestamp":1757305167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03234-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":217,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3234"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03234-3","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20180441","asserted-by":"subject"}]},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1425"}}